Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

12 de novembro de 2026 atualizado por: Merck Sharp & Dohme LLC

Um estudo multicêntrico de fase 1B/2 de fase 1B/2 para avaliar a segurança e a eficácia do raludotatug deRuxtecan com ou sem outros agentes de investigação anticâncer em participantes com o ovário epitelial de alto grau, o ovário da primeira quimioterapia peritoneal, ou o Fallopian, que retranspositou após a quimioterapia de platina anterior à platina anterior

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Visão geral do estudo

Descrição detalhada

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

Tipo de estudo

Intervencional

Inscrição (Estimado)

605

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Victoria
      • St Albans, Victoria, Austrália, 3021
        • Recrutamento
        • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
        • Contato:
          • Study Coordinator
          • Número de telefone: +61402775432
    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M9
        • Recrutamento
        • Princess Margaret Cancer Centre ( Site 0101)
        • Contato:
          • Study Coordinator
          • Número de telefone: 416-946-2818
    • Quebec
      • Montreal, Quebec, Canadá, H4A 3J1
        • Recrutamento
        • McGill University Health Centre ( Site 0100)
        • Contato:
          • Study Coordinator
          • Número de telefone: 514-934-1934x31975
      • Montreal, Quebec, Canadá, H2X 0A9
        • Recrutamento
        • Centre Hospitalier de l'Université de Montréal ( Site 0102)
        • Contato:
          • Study Coordinator
          • Número de telefone: 514-890-8000
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital ( Site 2000)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82220723511
      • Seoul, Coréia do Sul, 03722
        • Recrutamento
        • Severance Hospital, Yonsei University Health System ( Site 2002)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82222282230
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center ( Site 2003)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82230103646
      • Seoul, Coréia do Sul, 06351
        • Recrutamento
        • Samsung Medical Center ( Site 2001)
        • Contato:
          • Study Coordinator
          • Número de telefone: 82234101382
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Coréia do Sul, 10408
        • Recrutamento
        • National Cancer Center ( Site 2004)
        • Contato:
          • Study Coordinator
          • Número de telefone: 82319201760
      • Barcelona, Espanha, 08035
        • Recrutamento
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
        • Contato:
          • Study Coordinator
          • Número de telefone: +349325434528607
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hospital Universitario 12 de Octubre ( Site 0304)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34913908626
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
        • Contato:
          • Study Coordinator
          • Número de telefone: 34915504800 x2805
      • Málaga, Espanha, 29010
        • Recrutamento
        • Hospital Universitario Virgen de la Victoria ( Site 0306)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34951032508
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espanha, 08908
        • Recrutamento
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34932607744
    • Madrid
      • Majadhonda, Madrid, Espanha, 28222
        • Recrutamento
        • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34 911917358
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espanha, 28027
        • Recrutamento
        • Clinica Universidad de Navarra ( Site 0301)
        • Contato:
          • Study Coordinator
          • Número de telefone: +349135319207513
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Espanha, 46014
        • Recrutamento
        • Hospital General Universitario de Valencia ( Site 0305)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34 963187527
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Recrutamento
        • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
        • Contato:
          • Study Coordinator
          • Número de telefone: 203-785-2404
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • Recrutamento
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
        • Contato:
          • Study Coordinator
          • Número de telefone: 502-562-3429
    • Louisiana
      • Shreveport, Louisiana, Estados Unidos, 71103
        • Recrutamento
        • TRIALS 365 ( Site 0020)
        • Contato:
          • Study Coordinator
          • Número de telefone: 318-408-1198
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana-Farber Cancer Institute ( Site 0015)
        • Contato:
          • Study Coordinator
          • Número de telefone: 877-338-7425
    • New York
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center ( Site 0003)
        • Contato:
          • Study Coordinator
          • Número de telefone: 212-639-2000
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Recrutamento
        • OU Health University of Oklahoma Medical Center ( Site 7000)
        • Contato:
          • Study Coordinator
          • Número de telefone: 405-271-1112
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Recrutamento
        • Texas Oncology - DFW ( Site 8000)
        • Contato:
          • Study Coordinator
          • Número de telefone: 615-329-7430
      • Houston, Texas, Estados Unidos, 77030
        • Concluído
        • Houston Methodist Hospital ( Site 0010)
    • Utah
      • West Valley City, Utah, Estados Unidos, 84119
        • Recrutamento
        • START Mountain Region ( Site 0008)
        • Contato:
          • Study Coordinator
          • Número de telefone: 801-907-4750
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Recrutamento
        • University of Virginia Health System ( Site 0011)
        • Contato:
          • Study Coordinator
          • Número de telefone: 434-924-9333
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Health Care Campus ( Site 0202)
        • Contato:
          • Study Coordinator
          • Número de telefone: 972-4-7776234
      • Jerusalem, Israel, 9103102
        • Recrutamento
        • Shaare Zedek Medical Center ( Site 0201)
        • Contato:
          • Study Coordinator
          • Número de telefone: +972-(0)2-6555424
      • Petah Tikva, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center ( Site 0203)
        • Contato:
          • Study Coordinator
          • Número de telefone: +97239378076
      • Ramat Gan, Israel, 5265601
        • Recrutamento
        • Sheba Medical Center ( Site 0200)
        • Contato:
          • Study Coordinator
          • Número de telefone: 972-3-5304498
      • Manchester, Reino Unido, M20 4BX
        • Recrutamento
        • The Christie NHS Foundation Trust ( Site 0405)
        • Contato:
          • Study Coordinator
          • Número de telefone: +441619187689
    • East Sussex
      • Brighton, East Sussex, Reino Unido, BN2 1ES
        • Recrutamento
        • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
        • Contato:
          • Study Coordinator
          • Número de telefone: +44 01273 696 955
    • England
      • Fulham, England, Reino Unido, SW3 6JJ
        • Recrutamento
        • Royal Marsden Hospital ( Site 0402)
        • Contato:
          • Study Coordinator
          • Número de telefone: +442078118084
      • Sutton, England, Reino Unido, SM2 5PT
        • Recrutamento
        • The Royal Marsden NHS Foundation Trust. ( Site 0403)
        • Contato:
          • Study Coordinator
          • Número de telefone: +442078118084
    • London, City of
      • London, London, City of, Reino Unido, E1 1RD
        • Recrutamento
        • Barts Health NHS Trust ( Site 0401)
        • Contato:
          • Study Coordinator
          • Número de telefone: 020 7377 7000
      • London, London, City of, Reino Unido, SE1 3SS
        • Recrutamento
        • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
        • Contato:
          • Study Coordinator
          • Número de telefone: +44 020 7188 7188
      • Sankt Gallen, Suíça, 9000
        • Recrutamento
        • HOCH Health Ostschweiz ( Site 0801)
        • Contato:
          • Study Coordinator
          • Número de telefone: +41714941111
    • Canton of Basel-City
      • Basel, Canton of Basel-City, Suíça, 4031
        • Recrutamento
        • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
        • Contato:
          • Study Coordinator
          • Número de telefone: +41613284214
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Suíça, 1011
        • Recrutamento
        • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
        • Contato:
          • Study Coordinator
          • Número de telefone: +41795567362
      • Taipei, Taiwan, 100225
        • Recrutamento
        • National Taiwan University Hospital ( Site 3001)
        • Contato:
          • Study Coordinator
          • Número de telefone: +886223123456
      • Taoyuan, Taiwan, 33305
        • Recrutamento
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
        • Contato:
          • Study Coordinator
          • Número de telefone: +88633281200

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receives chronic steroid treatment
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active CNS metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Experimental: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Experimental: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Experimental: Cohort B-1 (R-DXd + Bevacizumab)

Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®
Experimental: Cohort B-2 (R-DXd RP2D + Bevacizumab)

Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®
Experimental: Cohort C-1 (R-DXd + Pembrolizumab)

Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Experimental: Cohort D (R-DXd +/- Bevacizumab)

Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®
Experimental: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®
Experimental: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®
Comparador Ativo: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®

IV injection on days 1 and 8 of each 3-week Cycle

IV injection administered on Day 1 of each 4-week cycle

Outros nomes:
  • PLD
Experimental: Cohort E-1 (R-DXd + MK-2010)

Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle

Experimental: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Experimental: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Experimental: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle.

Outros nomes:
  • Inclui, com base na fonte:
  • - Avastin®
  • -Alymsys®
  • - MVASI®
  • - Oyavas®
  • -Zirabev®
  • - Vegzelma®
  • - Aybintio®
  • -Breztri®

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Prazo: Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Prazo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Up to approximately 3 years
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Prazo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Objective Response Rate (ORR)
Prazo: Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Prazo: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Part 1: Objective Response Rate (ORR)
Prazo: Up to approximately 3 years

ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

Up to approximately 3 years
Part 2: Duration of Response (DOR)
Prazo: Up to approximately 3 years

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Prazo: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years
Part 2: Overall Survival (OS)
Prazo: Up to approximately 5 years

OS is defined as the time from the first dose of study treatment to death due to any cause.

Up to approximately 5 years
Part 2: Number of Participants with One or More AEs
Prazo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Prazo: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de abril de 2025

Conclusão Primária (Estimado)

27 de março de 2029

Conclusão do estudo (Estimado)

7 de fevereiro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

20 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de fevereiro de 2025

Primeira postagem (Real)

25 de fevereiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever